Wellington Management Group LLP Has $211.15 Million Position in Structure Therapeutics Inc. (NASDAQ:GPCR)

Wellington Management Group LLP lifted its holdings in Structure Therapeutics Inc. (NASDAQ:GPCR) by 0.2% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 7,785,614 shares of the company’s stock after purchasing an additional 15,843 shares during the quarter. Wellington Management Group LLP owned about 0.14% of Structure Therapeutics worth $211,146,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of the business. ANTIPODES PARTNERS Ltd boosted its holdings in shares of Structure Therapeutics by 115.0% in the fourth quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company’s stock valued at $28,000 after buying an additional 553 shares during the period. GAMMA Investing LLC lifted its position in Structure Therapeutics by 4,155.6% in the 4th quarter. GAMMA Investing LLC now owns 1,149 shares of the company’s stock valued at $31,000 after acquiring an additional 1,122 shares in the last quarter. FNY Investment Advisers LLC bought a new position in Structure Therapeutics during the 4th quarter worth about $40,000. Assetmark Inc. raised its stake in shares of Structure Therapeutics by 72.3% in the 4th quarter. Assetmark Inc. now owns 2,271 shares of the company’s stock valued at $62,000 after purchasing an additional 953 shares during the period. Finally, Jones Financial Companies Lllp lifted its holdings in shares of Structure Therapeutics by 29.8% in the fourth quarter. Jones Financial Companies Lllp now owns 4,228 shares of the company’s stock valued at $115,000 after purchasing an additional 971 shares in the last quarter. 91.78% of the stock is owned by institutional investors.

Structure Therapeutics Price Performance

Shares of GPCR stock opened at $16.95 on Thursday. The company has a fifty day moving average price of $23.52 and a two-hundred day moving average price of $30.73. Structure Therapeutics Inc. has a one year low of $15.31 and a one year high of $62.74. The stock has a market cap of $971.96 million, a P/E ratio of -22.91 and a beta of -2.37.

Structure Therapeutics (NASDAQ:GPCR) last issued its earnings results on Thursday, February 27th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.01. As a group, equities research analysts anticipate that Structure Therapeutics Inc. will post -0.82 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on GPCR. HC Wainwright reiterated a “buy” rating and set a $80.00 price objective on shares of Structure Therapeutics in a report on Thursday, December 19th. William Blair assumed coverage on shares of Structure Therapeutics in a research note on Friday, February 28th. They set an “outperform” rating for the company. JMP Securities reissued a “market outperform” rating and issued a $91.00 price objective on shares of Structure Therapeutics in a research report on Wednesday, December 18th. Finally, Stifel Nicolaus initiated coverage on shares of Structure Therapeutics in a report on Wednesday, January 8th. They set a “buy” rating and a $50.00 target price for the company. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $81.29.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.